

An Tran-Duy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7287955/publications.pdf>

Version: 2024-02-01

35
papers

707
citations

758635

12
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

1172
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review. <i>Quality of Life Research</i> , 2022, 31, 79-89.	1.5	9
2	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. <i>Medical Decision Making</i> , 2022, 42, 599-611.	1.2	5
3	Impact of Comorbid Conditions on Healthcare Expenditure and Work-related Outcomes in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1221-1229.	1.0	5
4	Measuring the economic impact of hospital-acquired complications on an acute health service. <i>Australian Health Review</i> , 2021, 45, 135-142.	0.5	15
5	Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e015816.	1.6	7
6	Development of a life expectancy table for individuals with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2228-2236.	2.9	10
7	Development and Use of Prediction Models for Classification of Cardiovascular Risk of Remote Indigenous Australians. <i>Heart Lung and Circulation</i> , 2020, 29, 374-383.	0.2	5
8	A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1741-1749.	4.3	12
9	Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. <i>Journal of Internal Medicine</i> , 2019, 285, 205-214.	2.7	33
10	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312.	1.7	28
11	PDB102 MODELLING PROGRESSION OF RISK FACTORS IN PATIENTS WITH TYPE 1 DIABETES: TOWARDS THE MOST APPROPRIATE FUNCTIONAL FORMS FOR A SIMULATION MODEL OF LONG-TERM HEALTH OUTCOMES. <i>Value in Health</i> , 2019, 22, S157.	0.1	0
12	Chewing gum to treat postoperative nausea and emesis in female patients (CHEWY): rationale and design for a multicentre randomised trial. <i>BMJ Open</i> , 2019, 9, e027505.	0.8	5
13	Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial. <i>BMJ Open</i> , 2019, 9, e033718.	0.8	7
14	PSY13 IMPACT OF COMORBID CONDITIONS ON HEALTH CARE EXPENDITURE AND WORK-RELATED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE ANALYSIS USING THE MEDICAL EXPENDITURE PANEL SURVEY IN THE PERIOD 2006-2015. <i>Value in Health</i> , 2019, 22, S376.	0.1	1
15	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.1	63
16	Longevity of outstanding sporting achievers: Mind versus muscle. <i>PLoS ONE</i> , 2018, 13, e0196938.	1.1	7
17	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. <i>Arthritis and Rheumatology</i> , 2018, 70, 1557-1564.	2.9	17
18	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 790.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout. <i>Journal of Rheumatology</i> , 2017, 44, 91-94.	1.0	1
20	Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1660-1669.	0.8	34
21	Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1706-1719.e5.	2.4	158
22	Implementation of Population Dynamics In Modelling Health And Budget Impact of An Intervention for A Chronic Disease With Multiple Disease Subtypes. <i>Value in Health</i> , 2015, 18, A700.	0.1	0
23	Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2015, 67, 1578-1585.	1.5	17
24	Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor- α antagonists in management of ankylosing spondylitis: a dynamic population modelling study. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 18.	0.6	4
25	Health and Utilities in Patients With Gout Under the Care of a Rheumatologist. <i>Arthritis Care and Research</i> , 2015, 67, 1128-1136.	1.5	8
26	Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis. <i>International Journal of Clinical Practice</i> , 2015, 69, 1088-1111.	0.8	19
27	Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015, 11, 896-905.	0.4	19
28	Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study. <i>Value in Health</i> , 2015, 18, A378.	0.1	0
29	Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2014, 32, 1015-1028.	1.7	9
30	How to Select the Right Cost-Effectiveness Model?. <i>Pharmacoeconomics</i> , 2014, 32, 429-442.	1.7	9
31	How to Select the Right Cost-Effectiveness Model? A Systematic Review and Stepwise Approach for Transferring an Existing Health Economic Model for Rheumatoid Arthritis. <i>Value in Health</i> , 2013, 16, A590.	0.1	0
32	Feed intake, growth and metabolism of Nile tilapia (<i>Oreochromis niloticus</i>) in relation to dissolved oxygen concentration. <i>Aquaculture Research</i> , 2012, 43, 730-744.	0.9	38
33	A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2111-2118.	0.5	11
34	Effects of oxygen concentration and body weight on maximum feed intake, growth and hematological parameters of Nile tilapia, <i>Oreochromis niloticus</i> . <i>Aquaculture</i> , 2008, 275, 152-162.	1.7	106
35	Effects of dietary starch and energy levels on maximum feed intake, growth and metabolism of Nile tilapia, <i>Oreochromis niloticus</i> . <i>Aquaculture</i> , 2008, 277, 213-219.	1.7	44